+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global ENT Disorder Treatment Market 2021-2025

  • PDF Icon

    Report

  • 120 Pages
  • March 2021
  • Region: Global
  • TechNavio
  • ID: 5004479
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global ENT disorder treatment Market 2021-2025

The publisher has been monitoring the ENT disorder treatment market and it is poised to grow by $ 9.09 bn during 2021-2025,decelerating at a CAGR of 13% during the forecast period. The report on ENT disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rapid environmental deterioration resulting in several allergic conditions, increasing geriatric population, and recent product approvals. In addition, rapid environmental deterioration resulting in several allergic conditions is anticipated to boost the growth of the market as well.

The ENT disorder treatment market analysis includes type segment and geographical landscapes.

The ENT disorder treatment market is segmented as below:

By Geographical Landscapes
  • North America
  • Europe
  • Asia
  • ROW

By Type
  • Rhinitis
  • Sinusitis
  • Otitis media
  • Tonsillitis

This study identifies the growing awareness among people about ENT disorder treatment as one of the prime reasons driving the ENT disorder treatment market growth during the next few years. Also, strategic mergers and acquisitions and advances in research on allergic disorders will lead to sizable demand in the market.

The report on ENT disorder treatment market covers the following areas:
  • ENT disorder treatment market sizing
  • ENT disorder treatment market forecast
  • ENT disorder treatment market industry analysis

The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading ENT disorder treatment market vendors that include AbbVie Inc., ALK-Abello AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., and Sanofi SA. Also, the ENT disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Market characteristics
  • COVID-19 impact on healthcare sector
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020-2025

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Indication
  • Market segments
  • Comparison by Indication
  • Rhinitis - Market size and forecast 2020-2025
  • Sinusitis - Market size and forecast 2020-2025
  • Otitis media - Market size and forecast 2020-2025
  • Tonsillitis - Market size and forecast 2020-2025
  • Market opportunity by Indication

Customer Landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • ALK-Abello AS
  • Bayer AG
  • Covis Pharma BV
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Other1 - Market share 2020-2025 (%)
  • Comparison by Other1
  • Rhinitis - Market size and forecast 2020-2025 ($ million)
  • Rhinitis - Year-over-year growth 2020-2025 (%)
  • Sinusitis - Market size and forecast 2020-2025 ($ million)
  • Sinusitis - Year-over-year growth 2020-2025 (%)
  • Otitis media - Market size and forecast 2020-2025 ($ million)
  • Otitis media - Year-over-year growth 2020-2025 (%)
  • Tonsillitis - Market size and forecast 2020-2025 ($ million)
  • Tonsillitis - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Other1
  • Customer landscape
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Market share by geography 2020-2025 (%)
  • Geographic comparison
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Key customers
  • AbbVie Inc. - Segment focus
  • ALK-Abello AS - Overview
  • ALK-Abello AS - Product and service
  • ALK-Abello AS - Key offerings
  • ALK-Abello AS - Key customers
  • ALK-Abello AS - Segment focus
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Key customers
  • Bayer AG - Segment focus
  • Covis Pharma BV - Overview
  • Covis Pharma BV - Product and service
  • Covis Pharma BV - Key offerings
  • Covis Pharma BV - Key customers
  • Covis Pharma BV - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Johnson & Johnson - Overview
  • Johnson & Johnson - Business segments
  • Johnson & Johnson - Key offerings
  • Johnson & Johnson - Key customers
  • Johnson & Johnson - Segment focus
  • Merck & Co. Inc. - Overview
  • Merck & Co. Inc. - Business segments
  • Merck & Co. Inc. - Key offerings
  • Merck & Co. Inc. - Key customers
  • Merck & Co. Inc. - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key offerings
  • Sanofi SA - Key customers
  • Sanofi SA - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global ENT disorder treatment market: AbbVie Inc., ALK-Abello AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., and Sanofi SA.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing awareness among people about ENT disorder treatment.'

According to the report, one of the major drivers for this market is the rapid environmental deterioration resulting in several allergic conditions.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • ALK-Abello AS
  • Bayer AG
  • Covis Pharma BV
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA